In the article by Bronwyn A. Kingwell et al, “Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity,” which published online April 12, 2022 (J Am Heart Assoc. 2022;11:e024754. DOI: 10.1161/JAHA.121.024754) and was included in the April 19, 2022 issue of the journal, a correction was needed.
On page 4 of the article, in the third line of the section “Plaque Stabilization,” the sentence reading “CSL111 is a predecessor compound formulated with higher apoA‐I/phosphatidylcholine molar ratio than CSL112.” was incorrect. It has now been corrected to read “CSL111 is a predecessor compound formulated with higher phosphatidylcholine/apoA‐I molar ratio than CSL112.”
The authors regret the error.
The online version of the article has been updated and is available here: